ArticleBMC neurology2026
Short-term outcomes of intracranial angioplasty with the Neuroform EZ stent in patients with hypoperfusion-related symptomatic intracranial atherosclerotic stenosis.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the safety profile and limitations of Neuroform EZ stenting in patients with hypoperfusion-related symptomatic intracranial atherosclerotic stenosis (ICAS), focusing on lesion morphology and risk stratification to identify patient subgroups that require stricter preoperative selection criteria.
methodsWe conducted a retrospective analysis of consecutive patients with hypoperfusion-related symptomatic ICAS who underwent Neuroform EZ stent placement at our institution between January 2020 and October 2023. The primary endpoint was the occurrence of any stroke or death within 30 days post-procedure. Secondary endpoints included technical success rate, incidence of ischemic stroke in the target artery territory from 30 days to 6 months post-procedure, and in-stent restenosis (ISR) rate during follow-up.
resultsA total of 64 patients (64 lesions) were included, all treated with Neuroform EZ stents. The technical success rate was 98.4%. The 30-day stroke or death rate was 6.2% (4/64). The incidence of ischemic stroke in the target artery territory from 30 days to 6 months post-procedure was 1.6% (1/64). During a mean follow-up of 10.4 ± 6.5 months, the ISR rate was 13.7% (7/51). Subgroup analysis revealed that the 30-day perioperative complication rate was significantly higher in patients with Mori type C lesions (25.0%, 4/16) than in those with Mori type A (0%, 0/16) or type B lesions (0%, 0/32) (Fisher's exact test, P = 0.002). Additionally, the ISR rate was significantly higher in Mori type C lesions (46.2%, 6/13) compared with Mori type A (0%, 0/14) or type B lesions (4.2%, 1/42) (Fisher's exact test, P < 0.001).
conclusionNeuroform EZ stenting may be a reasonable option for carefully selected patients with hypoperfusion-related ICAS and Mori type A/B lesions. However, its use in Mori type C lesions carries substantial periprocedural and restenosis risks and must be approached with extreme caution. These findings provide safety-focused risk stratification but require external validation, and do not prove that Neuroform EZ stenting is superior to standard medical therapy or other stent devices. Further controlled studies are required to validate these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.